Introduction
Changes in the understanding and in the clinical management of cystic fibrosis (CF) have increased life expectancy from single digits in the 1970s to more than 35 years at present (CF foundation, 2006) . As a consequence, new clinical problems have emerged, such as the increased bone fracture rate in adolescents and adults. These bone fractures are the result of a multitude of contributing factors such as lack of physical exercise, elevated cytokine production caused by chronic inflammation, delayed pubertal maturation, corticosteroid therapy, vitamin D and calcium deficiency, and a poor nutritional status (Aris et al., 2005) . Remarkably, because of the fact that vitamin D is fat soluble and most CF patients suffer from fat malabsorption, vitamin D deficiency is primarily blamed (Lark et al., 2001; Aris et al., 2005) . As a natural consequence, all nutritional guidelines insist on preventing this deficiency by means of a daily oral supplement (Borowitz et al., 2002; Sinaasappel et al., 2002; Aris et al., 2005) . Data on serum concentrations of 25-OH cholecalciferol (25 (OH) D) in CF are, however, not unequivocal, as they have been reported as too low by some authors (Donovan et al., 1998; Mortensen et al., 2000; Rovner et al., 2007) , whereas others disagree (Buntain et al., 2004; Chavasse et al., 2004) . Moreover, the failure of oral supplement treatments is common and has been widely published (Donovan et al., 1998; Boyle et al., 2005; Green et al., 2008; Green et al., 2010) . Holding fat malabsorption solely responsible for vitamin D deficiency overlooks the importance of the dermal supply, which in healthy people determines up to 85% of 25 (OH) D concentrations in conditions of sunshine (Heaney et al., 2003) . In less sunny regions, dermal vitamin D production is expected to be high during the sunnier months and low for the rest of the year (Rapuri et al., 2002) . Annual determination of 25 (OH) D concentrations, as is usually performed (Carr and Dinwiddie, 1996) , will thus only provide information about a single limited and recent period of time. In an attempt to understand the relative importance of different 25 (OH) D sources, more specifically the influence of sunlight, a retrospective study was undertaken, which looked at all available 25 (OH) D concentrations from the patients' annual follow-up visits, collected over 4 consecutive years. They were compared with values of healthy controls of the same age group and similar geographical latitude (latitude 501N). We hypothesize that sunlight will prove to be an important determinant of 25 (OH) D concentrations in CF patients.
Materials and methods
In a retrospective study design, a total of 474 values of 25 (OH) D serum concentrations from 141 CF patients was gathered. The values had been measured at the systematic annual follow-up visits between October 2001 and December 2005. For each patient the annual follow-up visit had taken place around the same time of the year. The group included all CF patients above the age of 1 year who were followed at the CF centre of the Ghent University Hospital (latitude 501N), without any selection. The group therefore contains every degree of disease severity. No transplanted patients were included. The median age was 15.6 years, ranging from 1 to 42 years; 56% of the patients were male. Based on fecal elastase 1 measurement, (Borowitz et al., 2004) 91% of the patients (n ¼ 128) had pancreatic insufficiency (o15 mg/g) and were being treated with pancreatic enzyme replacement, in accordance with guidelines (Sinaasappel et al., 2002) . Patients with fecal elastase 1 concentrations above 400 mg/g were regarded as pancreatic sufficient (7%). Faecal elastase 1 concentrations between 15 and 400 mg/g were considered equivocal and not taken into consideration (3%). Although a daily vitamin D supplement was prescribed to all patients regardless of exocrine pancreatic status, just only 93% reported taking it regularly (median dose: 800 IU cholecalciferol per day). The 25 (OH) D serum concentrations of 160 local (latitude 501N) healthy individuals, with a median age of 20 years (age range: 10-45 years), served as controls for the comparison with the values of CF patients measured during the 'Months with low ultraviolet B (UVB) exposure', from October to December.
Analysis
Venous blood samples were obtained. 25 (OH) D serum concentrations were determined after extraction by radioimmunoassay (DiaSorin, Stillwater, MN, USA). This assay shows 100% cross-reactivity between 25 (OH) D2 and 25 (OH) D3. In order to ascertain the importance of sunlight, 25 (OH) D serum concentrations were checked against the varying intensity of UVB light from the sun over the 4-year period. This information was retrieved from records at the Royal Meteorological Institute at the University Observatory Armand Pien, which is located within a 50 km distance from the place of residence of all patients in the study. Based on these records of varying intensity of UVB light, 1 year can be divided into two distinct periods: a period with less UVB exposure between November and April and a period with higher UVB exposure from May to October.
Statistical methods SPSS 12.0 (Chicago, IL, USA) was used in the statistical processing of the study data. As the data did not show a normal distribution, nonparametric tests were chosen. The correlation between 25 (OH) D serum concentrations and the varying intensity of UVB light was examined using the Spearman correlation coefficient. For the comparison between two groups, the Mann-Whitney U-test was used. The study was approved by the Medical Ethics board of the University Hospital at Ghent.
Results

Seasonal variations
The 474 values of 25 (OH) D serum concentrations from the annual follow-up visits (over the 4 years) were pooled and plotted per month ( Figure 1) . These values depicted an S-shaped curve, which was convex from May to October ('Months with high UVB exposure') and concave in the subsequent period from November to April ('Months with low UVB exposure'). The lowest values were seen in February.
The median 25 (OH) D serum concentrations during the 'Months with high UVB exposure' were significantly higher than those in the 'Months with low UVB exposure' (Table 1) .
There is an important fraction of the CF population with 25 (OH) D concentrations below 20 ng/ml (Table 2) . However, there is an important influence of the varying exposure to UVB light from the sun over the different years.
The 25 (OH) D serum concentrations were compared with reference values from healthy peers. No significant difference was found in comparison with local controls during the 'Months with low UVB exposure': CF patients: 18.0 ng/ml (interquartile range (IQR): 10.2-24.5 ng/ml); control group: 17.2 ng/ml (IQR: 12.7-19.3 ng/ml); P ¼ 0.60. During the 'Months with high UVB exposure', 25 (OH) D serum concentrations were not statistically inferior to values from a reported group of comparable age and geographical location (Guillemant et al., 2001 ).
Relation to sunshine hours
The comparison between the variation in 25 (OH) D serum concentrations in the CF group over the 4 years and the amount of UVB exposure in the preceding months showed a remarkably manifest correlation. It was clear that median 25 (OH) D serum concentrations ran parallel to the amount of Sunlight determines vitamin D concentration in CF E Robberecht et al UVB exposure in the 2 or 3 preceding months (Po0.001). It was also evident that in a year with more UVB exposure during the summer-such as 2003-25 (OH) D serum concentrations were higher than those recorded in a year with a summer with less UVB exposure (Figure 2 ).
Discussion
The past decade, a great amount of studies are published concerning vitamin D in CF. These publications mainly discuss the 25 (OH) D serum concentrations in CF patients. As the incidence of spontaneous bone fractures rises along with patient longevity, there is also a growing interest in the role of vitamin D in CF. The results presented in the different studies, however, are not unequivocal. The main source of confusion is disagreement on reference values to determine which values are too low. In most studies, 25 (OH) D serum concentrations are considered normal when above 20 ng/ml (Malabanan et al., 1998) , whereas more recently values above 30 ng/ml at any time of the year are recommended (Aris et al., 2005; Green et al., 2008) . It is not entirely clear on what basis those recommendations are made, whereas at the same time, in most surveys, these levels are not met by large groups of healthy people. Depending on geographical location, age and season, between 22 and 97% of 25 (OH) D serum concentrations in healthy controls are below 20 ng/ml (Andersen et al., 2005; Cashman, 2007) . It is therefore to be expected that at least as many people with CF will also have 25 (OH) D serum concentrations under the recommended values. Just as it occurs in healthy people, the percentages of 25 (OH) D serum concentrations below 20 ng/ml observed in CF patients can vary considerably from one study to another because of disparity in disease severity, Sunlight determines vitamin D concentration in CF E Robberecht et al age, geographical location and season (Buntain et al., 2004; Gronowitz et al., 2004; Boyle et al., 2005; Rovner et al., 2007) . In this study the difference between the percentages of 25 (OH) D serum concentrations below 20 ng/ml in the 4 successive years amounted to 58% exclusively because of sunshine variations. As vitamin D insufficiency (that is,: 25 (OH) D serum concentrations below the theoretically recommended 30 ng/ml (Rovner et al., 2007) ) is widespread even in healthy controls, preference was given to a comparison of actual serum concentrations in order to determine whether 25 (OH) D serum concentrations in patients with CF are significantly different from those in healthy people. We find no statistical difference in 25 (OH) D serum levels between people with CF and healthy controls. This seems to confirm results from other studies (Buntain et al., 2004) . These findings have important implications for clinical practice as they allow comparison of 25 (OH) D serum concentrations from CF patients with values from healthy controls, always taking into account the season of the year. It should be kept in mind that these conclusions are based on data from CF patients who were systematically taking a daily oral vitamin D supplement and from a healthy control population taking none. We found a significant difference in 25 (OH) D concentrations when we compared 'Months with high UVB exposure' with 'Months with low UVB exposure'. We found those differences as well in the patient group as in the healthy controls. The total amount of UV light during the period May-October at our location is approximately 5889 J/cm 2 (estimated amount of UVB light 589 J/cm 2 ) and the total amount of UV light during the period November-April is approximately 1761 J/cm 2 (estimated amount of UVB light 176 J/cm 2 ). The curve of 25 (OH) D serum concentrations and that of varying intensity of UVB light from the sun run a parallel course with a time-lag of approximately 2 months, as was also described in healthy people (Need et al., 1993) . A maximum is reached in late summer and a minimum at the end of the winter. Higher 25 (OH) D serum concentrations in September correlate with higher 25 (OH) D serum concentrations in March of the subsequent year. This is explained by the storage of 25-OH cholecalciferol from dermal sun exposure during the months with high UVB exposure and consumption during the months with less UVB exposure, resulting in a progressive depletion of stocks (Guillemant et al., 2001; Rapuri et al., 2002) . It is generally accepted that the skin is the major source of vitamin D, probably more than 85% of 25 (OH) D is obtained through exposure to sunlight (Heaney et al., 2003) . Exposure of 6% of the body surface to one minimal erythemal dose of sunlight is equivalent to the oral administration of 600-1000 IU of vitamin D. This means that, in conditions of sunshine, mild sun exposure of hands, arms, face or back, 2-3 times per week, would comply with vitamin D recommendations (Holick, 1996 (Holick, , 1999 . This is certainly feasible in sunny climates, whereas in regions with less sunny climates, it is only possible during some months of the year, and oral supplements thus remain imperative.
The data obtained in this study suggest that the current practice of supplementing CF patients can result in 25 (OH) D serum concentrations similar to those found in healthy controls. However, if concentrations constantly above 30 ng/ml are to be reached, as recommended, (Aris et al., 2005) current guidelines seem inadequate, and a supplementation with higher doses of vitamin D would be required. This brings us to the problem that in CF patients it proves extremely difficult to correct low 25 (OH) D serum concentrations with the aid of oral supplements Green et al., 2008 Green et al., , 2010 . High doses of oral vitamin D supplements for example, 50 000 IU of ergocalciferol daily for 28 days was effective in correcting vitamin D insufficiency in 50% of the subjects. However, almost half of the successfully Sunlight determines vitamin D concentration in CF E Robberecht et al treated patients were unable to maintain normal 25 (OH) D levels more than 6 months after completion of the therapy (Green et al., 2010) . A recent study of Khazai et al. (2009) , compared three treatment modes to correct low 25 (OH) concentrations. These were 50 000 IU of ergocalciferol weekly, 50 000 IU cholecalciferol weekly or treatment with UV light five times a week. Serum was collected for 25 (OH) D at baseline and at 12 weeks. Treatment with ergocalciferol and cholecalciferol raised 25 (OH) D significantly, treatment with UV did not raise 25 (OH) D significantly, however, only 55% of subjects were adherent with UV therapy. However, in other studies different methods of UVB exposure have been proved to be effective in increasing 25 (OH) D serum concentrations (Gronowitz et al., 2005; Chandra et al., 2007) .
Treatment with high doses of vitamin D may have at least a temporary result, further investigations to determine a possible role of treatment with UVB therapy are needed.
Conclusion
This study shows the prominent role of sunlight exposure in determining the levels of 25 (OH) D serum concentrations in CF patients. Concentration values reflect the previous amount of UVB exposure with a time-lag of approximately 2 months. Comparison of 25 (OH) D serum concentrations in both groups (CF patients and healthy controls) showed no significant difference, on condition that the period of the year be taken into account. As a consequence of the general recommendation that 25 (OH) D serum concentrations should stay above 30 ng/ml, a large percentage of controls and CF patients are labeled as vitamin D insufficient, especially during the months with less UVB exposure. Currently recommended daily oral supplements of 400-1000 IU are unable to correct this and therefore a higher oral vitamin D dose (1000-2000 IU cholecalciferol) should systematically be administered. A number of publications suggest that phototherapy could be a promising alternative still awaiting the development of adequate methods of application. In the meantime, prudent sunlight exposure, the natural form of phototherapy, should be encouraged during the months with a high UVB exposure.
